ChiCTR2300073759 版本V1.1 版本创建时间2023/09/16 09:47:14 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300073759 

最近更新日期:

Date of Last Refreshed on:

2023-07-20 10:36:06 

注册时间:

Date of Registration:

2023-07-20 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于fNIRS和多模态fMRI的青少年抑郁自杀风险预测及干预的脑效应机制研究

Public title:

Brain effect mechanism of adolescent depression suicide risk prediction and intervention based on fNIRS and multimodal fMRI

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于fNIRS和多模态fMRI的青少年抑郁自杀风险预测及干预的脑效应机制研究

Scientific title:

Brain effect mechanism of adolescent depression suicide risk prediction and intervention based on fNIRS and multimodal fMRI

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘娇颖 

研究负责人:

舒燕萍 

Applicant:

Liu Jiaoying 

Study leader:

Shu Yanping 

申请注册联系人电话:

Applicant telephone:

+86 152 8465 0720

研究负责人电话:

Study leader's
telephone:

+86 139 8540 2340

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liujiaoying0418@163.com

研究负责人电子邮件:

Study leader's E-mail:

doctor_sue@yeah.net

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

贵州省贵阳市新添大道南段206号

研究负责人通讯地址:

贵州省贵阳市新添大道南段206号

Applicant address:

206 Section of Xintian Road South, Guiyang, Guizhou

Study leader's address:

206 Section of Xintian Road South, Guiyang, Guizhou

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

贵州省第二人民医院

Applicant's institution:

The Second People's Hospital of Guizhou Province

研究负责人所在单位:

贵州省第二人民医院

Affiliation of the Leader:

The Second People's Hospital of Guizhou Province

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[2022]12

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

贵州省第二人民医院人体试验伦理委员会

Name of the ethic committee:

Ethics Committee of the Second People's Hospital of Guizhou

伦理委员会批准日期:

Date of approved by ethic committee:

2022-03-10 00:00:00

伦理委员会联系人:

赵代伟

Contact Name of the ethic committee:

Zhao Daiwei

伦理委员会联系地址:

贵州省贵阳市新添大道南段206号

Contact Address of the ethic committee:

206 Section of Xintian Road South, Guiyang, Guizhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 139 8505 5911

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

贵州省第二人民医院

Primary sponsor:

The Second People's Hospital of Guizhou

研究实施负责(组长)单位地址:

贵州省贵阳市新添大道南段206号

Primary sponsor's address:

206 Section of Xintian Road South, Guiyang, Guizhou

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

贵州

市(区县):

Country:

China

Province:

Guizhou

City:

单位(医院):

贵州省第二人民医院

具体地址:

贵州省贵阳市新添大道南段206号

Institution
hospital:

The Second People's Hospital of Guizhou

Address:

206 Section of Xintian Road South, Guiyang, Guizhou

经费或物资来源:

自筹

Source(s) of funding:

self-funded

研究疾病:

抑郁症  

Target disease:

depression

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

基于fNIRS和fMRI来研究加速重复经颅磁刺激对青少年抑郁的症状、自杀风险及认知功能的作用及其脑效应机制研究  

Objectives of Study:

To explore the effect and mechanism of accelerated repetitive transcranial magnetic stimulation on young patients with depressive disorder based on fNIRS and fMRI.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

患者组: (1)年龄 12-20 岁,汉族,右利手; (2)根据精神与行为障碍分类诊断为“抑郁症”; (3)1 月内未接受过抗抑郁治疗,无电休克治疗史及经颅磁刺激治疗史。 (4)HAMD17 评分≥17 分; (5)无电子、金属器械植入(心脏起搏器、除颤器、钢板等); (6)签署知情同意书 。 健康组: (1)汉族,年龄12-20岁,右利手,小学及以上文化程度; (2)HAMD17评分<7分; (3)HAMA14评分<7分; (4)无电子、金属器械植入(心脏起搏器、除颤器等)。

Inclusion criteria

Patient group: (1)12-20 years old, the Han nationality, right handed; (2) Diagnosed depression according to the ICD-10; (3) Have not received antidepressant treatment within one month, and have no history of electroconvulsive therapy or transcranial magnetic stimulation therapy. (4) HAMD-17 score >= 17; (5) No electronic or metal device implantation (pacemakers, defibrillators, steel plates, etc.) (6) Signed informed consent and be able to comply with the treatment plan. Healthy group: (1) Han Chinese, aged 12-20 years old, right-handed, with a primary school or above education level; (2) HAMD17 score<7 points; (3) HAMA14 score<7 points; (4) No electronic or metal device implantation (pacemaker, defibrillator, etc.).

排除标准:

患者组: (1)患有其他精神障碍,如精神发育迟滞、精神分裂症等; (2)HAMD17 评分<8 分; (3)患脑器质性疾病或严重躯体疾病或有物质依赖史; (4)抑郁症状为其它器质性疾病或药物所致; (5)存在 fMRI 及 fNIRS 检查禁忌,妊娠期女性; 健康组: (1)患有抑郁障碍、焦虑障碍、精神发育迟滞、精神分裂症等精神障碍; (2)HAMD17评分>8分; (3)患有脑器质性疾病或严重躯体疾病; (4)有物质依赖史; (5)存在fMRI及fNIRS检查禁忌,妊娠期女性;

Exclusion criteria:

Patient group: (1) Suffering from other mental disorders, such as mental retardation, schizophrenia, etc; (2) HAMD-17 score <= 8; (3) With an organic or severe medical condition of the brain or a history of substance dependence; (4) Depressive symptoms due to other organic disorders or medications; (5) With contraindications to fMRI and fNIRS, such as pregnant women etc. Healthy group: (1) Suffering from mental disorders such as depression, anxiety, mental retardation, and schizophrenia; (2) HAMD17 score>8 points; (3) Suffering from organic brain diseases or severe physical diseases; (4) Have a history of Substance dependence; (5) There are contraindications for fMRI and fNIRS examinations in pregnant women;

研究实施时间:

Study execute time:

From 2023-01-01 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-01-01 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

实验组一

样本量:

30

Group:

Experimental Group One

Sample size:

干预措施:

双靶点

干预措施代码:

Intervention:

Double target

Intervention code:

组别:

实验组二

样本量:

30

Group:

Experimental Group Two

Sample size:

干预措施:

单靶点

干预措施代码:

Intervention:

Single target

Intervention code:

组别:

对照组

样本量:

30

Group:

Control Group

Sample size:

干预措施:

伪刺激

干预措施代码:

Intervention:

Sham stimulation

Intervention code:

组别:

健康组

样本量:

30

Group:

Healthy Control

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

贵州 

市(区县):

 

Country:

China

Province:

Guizhou

City:

单位(医院):

贵州省第二人民医院 

单位级别:

三甲 

Institution
hospital:

The Second People's Hospital of Guizhou

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

功能近红外

指标类型:

主要指标

Outcome:

fNIRS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

功能磁共振

指标类型:

主要指标

Outcome:

fMRI

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿抑郁量表

指标类型:

主要指标

Outcome:

HAMD

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

蒙哥马利量表

指标类型:

主要指标

Outcome:

Montgomery-Asperger Depression Rating Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿焦虑量表

指标类型:

次要指标

Outcome:

HAMA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

自杀意念量表

指标类型:

次要指标

Outcome:

Scale for Suicide Ideation, SSI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

正性与负性情感量表

指标类型:

次要指标

Outcome:

Positive and negative affect scale, PANAS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心理复原力量表

指标类型:

次要指标

Outcome:

Connor davidson resilience scale, CD-RISC

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁自评量表

指标类型:

次要指标

Outcome:

Self-rating depression cale, SDS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 12 years
最大 Max age 20 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

通过计算机和EXCEL软件产生随机数字表。

Randomization Procedure (please state who generates the random number sequence and by what method):

Decide a random number by the EXCEL software

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Resman

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Resman

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用CRF表录入受试者研究资料,所有研究资料均由课题负责单位统一保存

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF will be used to record data generated from the study,and will be kept by the primary sponsor

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-07-20 10:36:02